Jin Medical International Stock
Jin Medical International Ltd.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- China
- CEO
- Erqi Wang
- Employees
- 273
- Market cap
- $16 M
- IPO
- 28/03/2023
Jin Medical International Ltd. specializes in the conception, production, and worldwide distribution of mobility and daily living aids, including wheelchairs, for individuals with disabilities or restricted movement. Their product range additionally features oxygen concentrators and specialized bathing devices.…
Jin Medical International stock: price history
1D
-3.3%
1W
+1.0%
1M
+5.6%
6M
+4.0%
YTD
-52.7%
1Y
-67.8%
2Y
-95.3%
5Y
–
10Y
–
Ask the agents about Jin Medical International
Jin Medical International stock metrics
P/E
14.23
P/B
0.54
EV/EBITDA
38.74
RETURN ON EQUITY
-0.4%
NET MARGIN
-1.2%
DEBT/EQUITY
0.68
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
23.4%
FLOAT SHARES
1,831,117
AVG. DAILY VOLUME (30D)
93,310
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Jin Medical International stock
What does Jin Medical International do?
Jin Medical International Ltd. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in China.
The CEO is Erqi Wang, the company employs around 273 people.
The IPO was on 28/03/2023; the stock trades on NASDAQ under the ticker ZJYL.
Does Jin Medical International pay a dividend?
No, Jin Medical International currently does not pay a dividend.
Which stocks are comparable to Jin Medical International?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Sartorius, Solventum, Baxter International and Cooper Companies.
How can I get Jin Medical International stock analyzed?
Clicking "Analyze stock" lets five strategies assess Jin Medical International against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.